Mirati Therapeutics Inc (NASDAQ: MRTX) has announced results from a post hoc exploratory analysis of the Phase 2 study, MRTX-500 of sitravatinib combined with Bristol-Myers Squibb Co's (NYSE: BMY) Opdivo (nivolumab).
The trial included 68 patients with second or third-line non-squamous non-small cell lung cancer (NSCLC) who experienced clinical benefit on a prior checkpoint inhibitor (CPI) and subsequent disease progression.
The data were presented at the European Society for Medical Oncology Congress (ESMO21) 2021.
The combination therapy posted a median progression-free survival (PFS) was 5.7 months.
The median overall survival was 14.9 months, with 56% and 32% of these patients alive at one year and two years, respectively.
The objective response rate was 18%, with 3% of patients achieving a complete response and 15% of patients achieving a partial response.
The median duration of response was 12.8 months.
The sitravatinib and nivolumab combination was well-tolerated and consistent with what was previously reported.
Grade 3/4 treatment-related adverse events (TRAEs) were reported in 66% of patients. The rate of TRAEs leading to discontinuation was 22%
Mirati says that the results support its ongoing Phase 3 SAPPHIRE study evaluating the combo therapy in NSCLC patients who are resistant to immune checkpoint inhibitor therapy.
Interim overall survival readout is expected in 2H of 2022.
Price Action: MRTX stock is up 2.28% at $178.01 during the market session on the last check Monday.
See more from Benzinga
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.